{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:10Z","timestamp":1780638010694,"version":"3.54.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0136141","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T18:01:10Z","timestamp":1440093670000},"page":"e0136141","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects"],"prefix":"10.1371","volume":"10","author":[{"given":"Luciana Kase","family":"Tanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Shikanai","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda Leme","family":"Talib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Yamaguti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helcio","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner Farid","family":"Gattaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"AG Marson","year":"2007","journal-title":"Lancet"},{"issue":"Issue 1","key":"ref2","article-title":"Carbamazepine for acute and chronic pain in adults","author":"PJ Wiffen","year":"2011","journal-title":"Cochrane Database Syst Rev Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"JC Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"JC Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2222.2007.02742.x","article-title":"Delayed drug hypersensitivity reactions\u2014new concepts","volume":"37","author":"SJ Posadas","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/mol.63.3.732","article-title":"Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones","volume":"63","author":"DJ Naisbitt","year":"2003","journal-title":"Mol Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/pgmj.75.889.680","article-title":"Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins","author":"SG Edwards","year":"1999","journal-title":"Postgraduate medical journal"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0022-3565(25)32544-9","article-title":"Anticonvulsant toxicity in vitro: possible role of arene oxides","volume":"217","author":"S Spielberg","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/0006-2952(95)02009-8","article-title":"Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity","volume":"50","author":"VJ Green","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0090-9556(25)07375-1","article-title":"Bioactivation of carbamazepine in the rat in vivo: Evidence for the formation of reactive arene oxide(s)","volume":"24","author":"S Madden","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-9556(25)07827-4","article-title":"Metabolism of carbamazepine","volume":"10","author":"K Lertratanangkoon","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00008571-199406000-00005","article-title":"Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions","volume":"4","author":"A Gaedigk","year":"1994","journal-title":"Pharmacogenetics"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2174\/092986708785747535","article-title":"Expression and function of cytochrome p450-dependent enzymes in human skin cells","volume":"15","author":"JM Baron","year":"2008","journal-title":"Curr Med Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/FPC.0b013e328348c6f2","article-title":"PharmGKB summary: carbamazepine pathway","volume":"21","author":"CF Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/FPC.0b013e32834aeedb","article-title":"PharmGKB summary: phenytoin pathway","volume":"22","author":"CF Thorn","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","article-title":"Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1\/ABCB1","volume":"19","author":"S Ozawa","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","article-title":"Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations","volume":"7","author":"JA Goldstein","year":"1997","journal-title":"Pharmacogenetics"},{"key":"ref18","unstructured":"International HapMap Project [Internet]. 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/hapmap.ncbi.nlm.nih.gov\/\" xlink:type=\"simple\">http:\/\/hapmap.ncbi.nlm.nih.gov\/<\/ext-link>"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"E Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"A Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"F Santiago","year":"2010","journal-title":"Contact Dermatitis"},{"key":"ref22","article-title":"Inclusion Criteria","author":"M Mockenhaupt","year":"2014"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"M Pirmohamed","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome\u2026: ethnicity matters","volume":"6","author":"C Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"A Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"P Demoly","year":"2014","journal-title":"Allergy"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs\u2014An ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"K Brockow","year":"2013","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"ref28","first-page":"316","article-title":"A nontoxic and versatile protein salting-out method for isolation of DNA","volume":"17","author":"J Laitinen","year":"1994","journal-title":"Biotechniques"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1479-7364-4-4-278","article-title":"The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects","volume":"4","author":"SC Sim","year":"2010","journal-title":"Hum Genomics"},{"key":"ref30","first-page":"1257","article-title":"CYP2C9 allelic variants: Ethnic distribution and functional significance","author":"HG Xie","year":"2002","journal-title":"Advanced Drug Delivery Reviews"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083472","article-title":"Global pharmacogenomics: Distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population","volume":"9","author":"G Suarez-Kurtz","year":"2014","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2006.03.005","article-title":"Activation of T cells by carbamazepine and carbamazepine metabolites","volume":"118","author":"Y Wu","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1600-0536.2003.00065.x","article-title":"Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine","volume":"48","author":"A-Y Lee","year":"2003","journal-title":"Contact Dermatitis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"M McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"S-I Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e17063","DOI":"10.1371\/journal.pone.0017063","article-title":"The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected","volume":"6","author":"SDJ Pena","year":"2011","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1248\/yakushi.123.369","article-title":"Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR","volume":"123","author":"M Nishimura","year":"2003","journal-title":"Yakugaku Zasshi"},{"issue":"Database issue","key":"ref38","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"FF Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0139861","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0136141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:09:45Z","timestamp":1748574585000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0136141"}},"subtitle":[],"editor":[{"given":"Marie-Pierre","family":"Dub\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0136141","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0139861","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]}}}